La información sobre este estudio está en inglés.
Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.
Lithium to Prevent or Delay Dementia
Start: September 1, 2017
End: May 31, 2024
Enrollment: 80
What Is This Study About?
This phase 4 clinical trial will test lithium, a drug approved to treat mania, depression, and other mental disorders, as a possible treatment that may delay dementia onset or slow its progression in older adults with mild cognitive impairment (MCI). Participants will be randomly assigned to take either lithium (beginning at 150 mg per day) or a placebo for two years. Participants will receive a neurocognitive assessment, biomarker tests using blood and cerebrospinal fluid samples, and brain imaging, at the start and after each year of the study.
Do I Qualify To Participate in This Study?
Minimum Age: 60 Years
Maximum Age: N/A
Must have:
- Diagnosis of MCI
Must NOT have:
- Major psychiatric illness
- Major neurological illness (e.g., multiple sclerosis)
- Contraindication to lithium (e.g., renal insufficiency)
- Inability to complete neuropsychological testing due to nonremediable impairment such as blindness
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Need Help?
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Who Sponsors This Study?
Lead: Ariel Gildengers, MD
Collaborator Sponsor
- National Institute on Aging (NIA)
Source: ClinicalTrials.gov ID: NCT03185208